Review of Ocular Manifestations of Joubert Syndrome

Stephanie F. Wang 1, Tia J. Kowal 2, Ke Ning 2, Euna B. Koo 2, Albert Y. Wu 2,3,*, Vinit B. Mahajan 2,3 and Yang Sun 2,3,*

1 State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA; stephanie.wang@downstate.edu
2 Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Palo Alto, CA 94305, USA; tjkowal@stanford.edu (T.J.K.); vikaning@stanford.edu (K.N.); eunakoo@stanford.edu (E.B.K.); awu1@stanford.edu (A.Y.W.); vinit.mahajan@stanford.edu (V.B.M.)
3 Palo Alto Veterans Administration, Palo Alto, CA 94304, USA
* Correspondence: yangsun@stanford.edu

Received: 29 September 2018; Accepted: 27 November 2018; Published: 4 December 2018

Abstract: Joubert syndrome is a group of rare disorders that stem from defects in a sensory organelle, the primary cilia. Affected patients often present with disorders involving multiple organ systems, including the brain, eyes, and kidneys. Common symptoms include breathing abnormalities, mental developmental delays, loss of voluntary muscle coordination, and abnormal eye movements, with a diagnostic “molar tooth” sign observed by magnetic resonance imaging (MRI) of the midbrain. We reviewed the ocular phenotypes that can be found in patients with Joubert syndrome. Ocular motor apraxia is the most frequent (80% of patients), followed by strabismus (74%) and nystagmus (72%). A minority of patients also present with ptosis (43%), chorioretinal coloboma (30%), and optic nerve atrophy (22%). Although mutations in 34 genes have been found to be associated with Joubert syndrome, retinal degeneration has been reported in only 38% of patients. Mutations in AHI1 and CEP290, genes critical to primary cilia function, have been linked to retinal degeneration. In conclusion, Joubert syndrome is a rare pleiotropic group of disorders with variable ocular presentations.

Keywords: Joubert syndrome; primary cilia

1. Introduction

Joubert Syndrome (JS) is a rare, autosomal recessive disorder with findings of episodic hyperpnea, global developmental delays, ataxia, and abnormal eye movements first described by Marie Joubert in 1969 [1–3]. It is accompanied by a congenital malformation of the brainstem and cerebellar vermis that composes the pathognomonic finding of a “molar tooth sign” (MTS) on magnetic resonance imaging (MRI) of the brain (Figure 1A). Abnormal features that constitute MTS include cerebellar vermis hypoplasia, deepened interpeduncular fossa, and thickened and elongated superior cerebellar peduncles. There are many subtypes of JS and JS-related disorders where MTS is found that involve the brain, eyes, kidneys, liver, and limbs [4,5].

The heterogeneous clinical findings of this genetic disorder are due to defects in primary cilia, a subcellular organelle that is a component of all vertebrate cells. The primary cilium is a microtubule-based organelle that protrudes from the cell surface and acts as an antenna to sense the extracellular environment. Its pathogenesis places JS within an expanding spectrum of diseases termed ciliopathies [6,7]. Commonly found features in JS include ophthalmic and oculomotor abnormalities, which can be useful in establishing a diagnosis [2]. The diverse abnormal eye movements include
strabismus, nystagmus, oculomotor apraxia, and vertical gaze palsy. Several case reports have described retinal abnormalities (Figure 1A–C); among them are retinitis pigmentosa (RP), retinal dystrophy, chorioretinal colobomas, and retinal blindness [8–13]. This review will detail the ophthalmologic findings of JS.

![Figure 1](image_url)

**Figure 1.** Representative clinical ocular presentations of Joubert Syndrome. (A) Magnetic resonance imaging (MRI) T2-weighted image of the “Molar Tooth Sign” (white arrow). (B) Retinal dystrophy with maculopathy. (C) Coloboma of the optic disc, marked with a dashed line.

### 2. Epidemiology

Because of its rarity, there is little epidemiological data on JS, but it is reported to have a prevalence of between 1/80,000 and 1/100,000 live births [5,14,15]. This may be an underestimate due to its heterogeneous presentation [4].

The prevalence is higher in certain ethnic groups. These include French Canadians, in whom multiple pathogenic mutations in the C5ORF42 gene (also known as CPLANE1) have been reported since Joubert et al. described the initial cases in 1969 [16]. Pathogenic mutations were identified in 33/35 (94%) French Canadian families tested [17] and included the following genes: CPLANE1, CC2D2A, NPHP1, TMEM231, CEP290, TMEM67, TCTN1, OFD1, B9D1, C2CD3, and CEP104. Many French Canadian patients were found to be compound heterozygous for pathogenic mutations in the genes CPLANE1, CC2D2A, TMEM231, and NPHP1 [16–18].

The incidence of JS is also higher in Ashkenazi Jews and Hutterites [19,20]. The prevalence of JS is as high as 1/34,000–1/40,000 in Ashkenazi Jews because of the pathogenic mutation p.R73L in the TMEM216 gene, as well as a higher carrier frequency of 1:90–1:100 [19]. In the Canadian Hutterite population, the carrier frequency of a pathogenic mutation, the founder mutation p.R18X in the TMEM237 gene, is even greater at 1:17, which increases the prevalence of JS to approximately 1/1150 [20]. Additionally, two different Schmiedelevut Hutterite families share the same pathogenic mutation, c.363_364delTA in TMEM231, which indicates a separate founder variant [21]. An investigation of Japanese families with JS found that 22% had pathogenic mutations in CEP290, with c.6012-12T>A found on nine out of 12 disease alleles; 26% of families had pathogenic mutations in TMEM67 [22]. Thus, targeted analysis should be considered for these groups [4], as well as for the Dutch (founder mutation p.Arg2904Ter in CPLANE1) [14], French Canadian (variants in CPLANE1, CC2D2A, NPHP1, and TMEM231) [17], and Japanese (c.6012-12T>A mutation in CEP290) [22].

### 3. Clinical Classifications

The classic form of JS consists of a distinct triad of clinical signs: hypotonia, developmental delays, and pathognomonic midbrain–hindbrain malformation (MTS) on MRI [4]. Breathing abnormalities (episodic tachypnea or apnea) and/or unusual eye movements may be associated with the triad. The breathing abnormalities usually improve as the patient gets older, but truncal ataxia develops or becomes more apparent, and the attainment of age-appropriate motor skills is delayed [4]. Intellectual
capacity varies and can range from normal to severely disabled. Additional abnormalities that may be associated with JS include renal disease, occipital encephalocele, polydactyly, ocular colobomas, retinal dystrophy, hepatic fibrosis, oral hamartomas, and endocrine disorders [4].

Due to its heterogeneous, multi-organ pathology, JS is classified into eight phenotypic subgroups based on the main system(s) involved: pure JS, JS with renal abnormalities, JS with ocular abnormalities, JS with oculo-renal abnormalities, JS with orofaciodigital abnormalities, JS with hepatic defects, JS with acrocallosal features, and JS with Jeune asphyxiating thoracic dystrophy [4,5]. Just as the authors who originally designated these classification subtypes, we suggest that due to the heterogeneity of presentation of JS, these classifications should not be considered as definitive.

In the classic form of JS, patients exhibit muscle weakness/ataxia, developmental delay, and MTS along with variable degrees of abnormal breathing, eye movements, and cognitive ability. Renal, liver, and retinal disorders are absent [4]. Mutation in several genes has been found in these classic cases [4]. Patients with JS with ocular defects (JS-O) suffer from retinal dystrophy that varies in progression and severity in addition to the abnormalities of the classic form; $AHI1$ mutations are frequent in this subgroup [4].

Patients with JS with renal disease (JS-R) exhibit the features of a kidney disorder that is predominantly juvenile nephronophthisis (NPH), without defects in the retina; mutations of $NPHP1$ and $RPGRIP1L$ are associated with this phenotype. Patients with JS with oculorenal defects (JS-OR) suffer from retinal dystrophy and renal defects; $CEP290$ mutations account for approximately 50% of these presentations [4]. In JS with hepatic defects (JS-H), individuals also suffer from congenital hepatic fibrosis; ocular and renal defects may occur but are not required for inclusion in this subtype. Mutations in $TMEM67$ account for more than 70% of these cases [23,24]. In JS with orofaciodigital defects (JS-OFD), patients present with polydactyly, a bifid or lobulated tongue due to soft-tissue nodules or multiple hamartomas, and multiple oral frenulae. Hypothalamic hamartoma may occur, and the pituitary gland may be absent. This presentation is associated with mutations in the $TMEM216$ gene [5]. In JS with acrocallosal features (JS-AC), there is complete or partial absence of the corpus callosum [25]. One series reported corpus callosal abnormalities of varying degrees of severity in 16 of 20 cases with JS [26]. Callosal abnormalities are also relatively frequent in biallelic $KIF7$ pathogenic variants of JS [27], suggesting overlap with acrocallosal syndrome in which polydactyly and hydrocephalus are also seen.

Several cases of JS with Jeune asphyxiating thoracic dystrophy (JS-JATD) have been observed [28,29]. Symptoms of JATD, a rare autosomal recessive disorder, and of the related Mainzer–Saldino syndrome, include a long, narrow thorax; short stature with undersized limbs; polydactyly; and renal cystic dysplasia. The number of genes associated with JS continues to increase, along with greater recognition of the importance of cilia function in the development of multiple organ systems.

### 4. Genetics

Joubert Syndrome is categorized among the ciliopathies because its pathogenic genes generate proteins that are important in the function of primary cilia [30]. Twenty-eight identified genes are known to be involved in the pathogenesis of JS; most alleles are autosomal recessive. The most common genes are $AHI1$, $CC2D2A$, $CEP290$, $CPLANE1$, $CSPP1$, $INPP5E$, $KIAA0586$, $MKS1$, $NPHP1$, $RPGRIP1L$, $TMEM67$, and $TMEM216$. Less common genes include $ARL13B$, $B9D1$, $C2CD3$, $CEP104$, $CEP120$, $KIAA0556$, $OFD1$, $PDE6D$, $POC1B$, $TCTN1$, $TCTN3$, $TMEM138$, $TMEM231$, and $TMEM237$. These genes are important for establishing the clinical diagnosis of JS. A genetic diagnosis can be made in over 60% of individuals through identification of homozygous mutations in one of the 27 autosomal recessive genes or a heterozygous variant in the X-linked gene ($OFD1$) (Figure 2) [4].

Genetic testing that utilizes multigene panels for targeted examination of genes reported to be related to JS can therefore be applied. Alternatively, whole genome sequencing, which is more comprehensive, will aid in correctly diagnosing patients with JS. It is recommended that genetic testing begin with a multigene panel, and that genome sequencing be used if the multigene approach identifies
no known variations [31]. Sequence analysis, deletion/duplication analysis, and non-sequencing-based tests are often utilized in the multigene panel [4]. Genetic testing for mutations causing JS can aid clinicians to develop appropriate management plans based on the expected phenotypes associated with these genes.

In patients with classic JS or JS with ocular involvement, the genes most commonly mutated are AHI1, INPP5E, ARL13B, and CC2D2A [6,32]. The AHI1 protein has been found to maintain appropriate vesicular trafficking to cilia; this trafficking is necessary for the normal function of photoreceptor outer segments. Indeed, in mice, the retina deteriorates in the absence of AHI1 [33]. Interestingly, in a cohort of 100 JS patients, no retinal degeneration was observed in patients with TMEM67, C5orf42, or KIAA0586 mutations, which are among the most common identified with JS [31]. However, another study using a similar set of patients from the same clinical study identified patients with thinning of the retinal nerve fiber and optic pallor associated with mutation in KIAA0586 [34]. Additionally, a study of a cohort of Northern Europeans identified retinal dysplasia associated with mutation in TMEM67 [14]. Despite the heterogeneity in the genes involved, several ophthalmic phenotypes (Table 1) are common, including retinal dystrophies and oculomotor defects.

5. Ophthalmic Phenotypes/Presentation

We surveyed 52 publications examining a total of 325 patients that have been diagnosed as having ocular phenotypes. These studies did not consistently test for the same ocular phenotypes (Figure 3). Discrepancies in the testing performed for each patient may be due to patient availability or ability to cooperate in testing. These discrepancies create a challenge for clinicians and researchers alike as the diagnosis and reported prevalence of the disease may be variable or underestimated. Commonly diagnosed phenotypes include retinal dystrophy, abnormal retinal pigmentation, ocular colobomas, oculomotor apraxia, nystagmus, strabismus, and ptosis, and are described in more detail below. Although in several cases one gene may correspond to only one phenotype, in general the phenotypes associated with each gene overlap (Table 1 and Figure 4A).
| JS-Related Gene | Protein | No. of pts | OMA | Nystagmus | Coloboma | Retinopathy (Vision Reduced) | Microphthalmia (Dysplasia) | Abnormal Pigmentation | Myopia/Hyperopia | Strabismus | Ptosis | References (PMID) |
|----------------|---------|------------|-----|-----------|----------|------------------------------|---------------------------|------------------------|----------------|------------|------|------------------|
| AHI1 | Abelson helper integration site 1 | 36 | + | + | + | + | + | + | + | + | + | 28431631; 25920555; 26759440; 26541515; 16453322; 19461662; 19443711; 29857873; 21580116 |
| ARL13B | ADP-ribosylation factor-like 13B | 6 | + | | | | | | | | | 25138100; 29253582 |
| B9D1 | B9 domain containing 1 | 3 | + | | | | | | | | | 26477546; 24865560 |
| C2CD3 | C2 calcium dependent domain containing 3 | 2 | + | | | | | | | | | 26477546 |
| C3orf42 | CPLANE1, ciliogenesis and planar polarity effector 1 | 31 | + | + | | | | | | | | 28431631; 26477546; 25920555; 25173907; 27966038; 214178751 |
| CC2D2A | Coiled-coil and C2 domain containing 2A | 8 | + | + | + | | | | | | | 26477546; 25920555; 27959436; 25173907; 29887673 |
| CEP104 | Centrosomal protein 104 | 3 | + | | | | | | | | | 26477546 |
| CEP120 | Centrosomal protein 120 | 6 | + | + | | | | | | | | 27228211 |
| CEP290 | Centrosomal protein 290 | 7 | + | + | | | | | | | | 26477546; 25920555; 19461662; 25818971; 24850569 |
| JS-Related Gene | Protein | No. of pts | OMA | Nystagmus | Coloboma | Retinopathy (Vision Reduced) | Microphthalmia (Dysplasia) | Abnormal Pigmentation | Myopia/ Hyperopia | Strabismus | Ptosis | References (PMID) |
|----------------|---------|-----------|-----|-----------|---------|-------------------------------|---------------------------|------------------------|-------------------|------------|--------|-------------------|
| CLUAP1         | Clusterin associated protein 1 | 1       | +   |           |         |                               |                           |                        |                   |            |        | 28679688          |
| CSPP1          | Centrosome and spindle pole associated protein 1 | 25      | +   | +         | +       |                               |                           |                        |                   |            |        | 24360806; 24360807; |
| INPP5E         | Inositol polyphosphate-5-phosphatase E | 11      | +   | +         | +       | +                             |                           | +                      |                   |            |        | 25920555; 25818971; 29052317; 20446224; 29987673 |
| KIAA0556       | KIAA0556 | 5       | +   | +         |         |                               |                           |                        |                   |            |        | 27245168; 26714646 |
| KIAA0586       | KIAA0586 | 26      | +   | +         | +       | +                             |                           | +                      |                   |            |        | 26386247; 26386044; 26096313 |
| KIAA0753       | KIAA0753 | 2       | +   |           |         |                               |                           |                        |                   |            |        | 28220259          |
| MKS1           | Meckel syndrome, type 1 | 12      | +   | +         | +       | +                             |                           |                       |                   |            |        | 27377014; 26490104; 24896560 |
| NPHP1          | Nephrocytin 1 | 5       | +   |           |         |                               |                           |                        |                   |            |        | 26477546; 28347285; 23683649 |
| OFD1           | OFD1, centriole and centriolar satellite protein | 3       | +   |           |         |                               |                           |                        |                   |            |        | 26477546; 25920555; 28505661 |
| PDE6D          | Phosphodiesterase 6D | 3       | +   |           |         |                               |                           |                        |                   |            |        | 24166846          |
| POC1B          | POC1 centriolar protein B | 1       | +   | +         | +       | +                             |                           |                        |                   |            |        | 25044745          |
| RPGRIP1L       | RPGR interacting protein 1 | 5       | +   | +         |         |                               |                           |                        |                   |            |        | 25920555; 19461662; 18565997 |
Table 1. Cont.

| JS-Related Gene | Protein Description | No. of pts | OMA | Nystagmus | Coloboma | Retinopathy (Vision Reduced) | Microphthalmia (Dysplasia) | Abnormal Pigmentation | Myopia/Hyperopia | Strabismus | Ptosis | References (PMID)          |
|-----------------|---------------------|------------|-----|-----------|----------|----------------------------|---------------------------|-----------------------|-----------------|-----------|-------|---------------------------|
| TCTN1           | Tectonic family member 1 | 2          |     | +         |          |                            |                           |                       |                 |           |       | 26477546; 26489806        |
| TCTN3           | Tectonic family member 3 | 1          |     |           |          |                            |                           |                       |                 |           |       | 25118024                  |
| TMEM138         | Transmembrane protein 138 | 1          |     | +         |          |                            |                           |                       | +               |           |       | 28102635                  |
| TMEM231         | Transmembrane protein 231 | 1          |     |           |          |                            |                           |                       |                 |           |       | 25920555                  |
| TMEM237         | Transmembrane protein 237 | 19         |     | +         | +        |                            |                           |                       |                 |           |       | + (26489806)              |
| TMEM67          | Transmembrane protein 67 | 9          |     | +         |          |                            |                           |                       |                 |           |       | + (26477546; 26489806)    |
| AHI1/NPHP1      |                     | 1          |     | +         |          |                            |                           |                       |                 |           |       | 19443711                  |
| AHI1/TMEM67     |                     | 1          |     | +         |          |                            |                           |                       |                 |           |       | 25920555                  |
| TCTN3/TCTN2     |                     | 1          |     | +         |          |                            |                           |                       |                 |           |       | 25118024                  |
| Unknown gene    |                     | 8          |     | +         |          |                            |                           |                       |                 |           |       | + (28838911; 19461662)    |

OMA = Oculomotor apraxia. Number of patients = 245.
which also plays a well-documented role in ciliary signaling. The phenotypes of retinal dystrophy in photoreceptor cells [2,4,5], which contain primary cilia (“connecting cilia”)—slender structures that connect the outer and inner segments [30]. Patients with retinal dystrophy have a higher incidence of multicystic renal disease and a higher mortality rate than JS patients without retinal dystrophy [34].

Retinal dystrophy can commonly be detected by autofluorescence photos of the retina [35]. Optical coherence tomography (OCT) may provide another diagnostic technique with which to investigate retinal ciliopathies [36]. In one patient with JS this modality revealed blurred external retinal layers in the macula center, “salt-and-pepper” fundus, inner segment–outer segment junction (IS/OS line) discontinuity, and a lack of external limiting membrane [36].

The gene most commonly observed to cause retinal dystrophy is AHI1, followed by INPP5E, but a total of 14 genes have been reported to be responsible for this phenotype (Figure 4B). The AHI1 protein, also called Jouberin [37–40], contains a highly conserved SH3 domain, suggesting a possible role as a signaling molecule. Indeed, it is known to interact with NPHP1 and Meckle, and may be involved in ciliogenesis or ciliary transport. INPP5E encodes an inositol polyphosphate-5-phosphatase [40,41], which also plays a well-documented role in ciliary signaling. The phenotypes of retinal dystrophy in JS also include RP, optic disc drusen, and Leber congenital amaurosis (LCA).

6.1. Retinitis Pigmentosa

Retinitis pigmentosa in JS typically manifests as spotting of the retinal pigment epithelium (RPE) and the thinning and reduction of retinal vessels. The primary cause of this defect originates in the connecting cilia of the retinal photoreceptor cells and the modified cilia of the outer segment [30].

Atypical RPE changes, which are unlike those of RP, have also been reported in JS. In one case the midperipheral fundus revealed uniformly distributed hypopigmented discrete lesions resembling those of retinitis albipunctata. Coarse intraretinal pigmentation along the retinal venules and general narrowing of arterioles were also observed [42].
Figure 4. (A) Genetic overlap within the eye phenotypes of Joubert Syndrome. Most of the genes are associated with OMA and nystagmus. AP = Abnormal pigmentation. (B–H) Pie charts showing the prevalence of genetic causes in the entire group of 254 patients diagnosed with different eye phenotypes. Genes are listed from left to right in order of increasing prevalence.
Coats-like retinopathy has also been reported in one case of JS. The dilated and aneurysmal blood vessels of this exudative retinopathy were comparable to those of Coats disease, but more prominent in the inferior quadrants [43]. It was suggested that the Coats-like retinopathy may have been independent of JS, but Coats-like retinopathy has been previously described in association with LCA due to CEP290 mutation [44], which has also been linked with JS [45]. Similar retinal defects were found in three patients with Senior–Loken syndrome, which suggests that Coats-like retinopathy lies on the spectrum of retinal phenotypes present in ciliopathies [43]. Establishing the correct diagnosis is important for proper treatment as laser photocoagulation, cryotherapy, or vitreoretinal surgery can be performed in severe cases [43].

Other manifestations may include optic disc drusen, which seldom manifest in early childhood and which are infrequent congenital disc anomalies that are composed of hyaline substance and calcified deposits which accrue gradually over time. Only a few cases have been reported of JS with optic disc drusen; therefore, it is possible that the drusen occurred serendipitously in cases of JS and that the coexistence of JS and drusen should not be interpreted as an association until the pathophysiology of both is better understood [46]. Optic disc drusen should be suspected if optic disc swelling or elevation is observed without increased intracranial pressure [47,48]. Drusen are generally bilateral and occur with a prevalence of between 0.4 and 3.7% in a population that includes normal adults and children and of ~0.4% in the pediatric age group. In one case, orbital ultrasonography confirmed drusen in a 4-month-old patient with JS who presented with increased intracranial pressure. The procedure revealed suspicious hyperechoic lesions within both optic discs. The hyperechoic calcifications were more prominent with posterior shadowing compatible with drusen. In addition, it is intriguing that B-scan ultrasound and autofluorescence confirmed bilateral optic disc drusen in 2/10 subjects with JS; retinal dystrophy was also described in the first reported case of drusen in JS [11,49].

6.2. Leber Congenital Amaurosis

Leber congenital amaurosis is a severe retinal degeneration that causes extensive vision loss. Usually diagnosed soon after birth, it produces profound dysfunction of the two photoreceptor types, which leads to nystagmus, photophobia, reduced pupillary response, high hyperopia, and greatly reduced electroretinographic responses. Patients with LCA characteristically demonstrate a significantly greater than usual amount of eye poking and rubbing. This is described as Franceschetti’s oculo-digital sign and increases the risk of keratoconus in these patients [49,50]. Juvenile severe cone–rod or cone dystrophy (CORD, COD) and RP may be mistaken for LCA because of similar clinical features.

Variants of 30 genes that have been identified as causing photoreceptor cell death and LCA are responsible for approximately 62% of cases. Although LCA is usually inherited in an autosomal recessive manner, a few cases presented with dominant inheritance. It can also appear as one component of a syndrome, as in JS [49,51–56]. One study of a consanguineous Iraqi family identified POC1B, a gene that is critical for ciliogenesis and for maintaining basal body and centrosome integrity, as a possible cause of JS with LCA and a polycystic kidney disease phenotype [57]. In one case of suspected JS with LCA, morphological analysis revealed an atrophic maculopathy and a significant decrease in photoreceptor cells. The disorganized retina contained almost no rods and only a few surviving cones in the perifoveal region. Pigmentation was decreased in most regions of the retina, and the RPE layer was thinned in peripheral regions. RPE65, an enzyme expressed in RPE cells, was detected in the RPE layer and in the outer segment, but the RPE layer did not contain lipofuscin granules, which indicates defective lysosomal degradation of phagocytosed photoreceptors. Centrin-2, a protein found in the basal bodies of cilia, was also absent.

6.3. Abnormal Pigmentation

Abnormal pigmentation was reported in 4.5% of the patients with JS in the publications reviewed (11/245). About 72% (8/11) of these patients carried an AHI1 (5) or CEP290 (3) mutation (Figure 4,
Table 1); mutations were also detected in C5orf42 (1) and CC2D2A (1), and the genotype of one patient was unknown (Figure 4C). The fundi of these patients demonstrated bone spicule or mottled pigmentary irregularities in the peripheral or mid-peripheral retina, or in the entire retina. In the clinic, pigmentary retinopathy with nystagmus or roving eye movements is frequently diagnosed as LCA. Interestingly, CEP290 mutations also account for 20% of LCA (ref) [58], which may explain some of the overlap with other JS phenotypes. LCA, however, typically lacks a concomitant central nervous system disorder.

7. Ocular Colobomas

Ocular colobomas are defects that arise from the fetal fissure failing to close normally, which leads to missing tissue in the retinal pigmented epithelium, the neurosensory retina, or the choroid [59]. These defects can be unilateral or bilateral, can affect the optic disc and/or choroid, and are most commonly localized to the posterior part of the eye [14,27,31,57,60–67]. Colobomas involving the iris have also been observed [68]. Colobomas comprise only a small subset of ocular defects across the JS subtypes, but have been reported in over 30% of JS patients with hepatic defects [69] and may also be associated with hepatic fibrosis [23]. Additionally, in a survey of 100 JS patients, chorioretinal coloboma was found to be associated with a decreased risk for retinal degeneration and increased risk for liver disease [31].

Differences in the incidence of coloboma between cohorts have also been observed. One study found that colobomas affected 19% of families with JS [70]. Another reported an incidence of 30% (28/99), with 20/28 involving the retina; those with the TMEM67 mutation had the highest incidence (80%) [35]. The consensus in the literature is that only ~3% of patients with JS have both coloboma and retinal degeneration [27,35,71].

Although the incidence of ocular colobomas is small, mutations in several genes have been identified in patients with this diagnosis (Figure 4D). These genes include MSK1, INPP5E, ODF1, PDE6D, POC1B, AHI1/TMEM67, TMEM237, KIAA0586, CEP290, and TMEM67. The gene associated with the greatest number of patients with ocular colobomas is TMEM67 (Meckelin). This transmembrane protein plays an important role in ciliogenesis and signaling.

7.1. Oculomotor Defects

7.1.1. Oculomotor Apraxia

Common in JS is a distinct collection of neuro-ophthalmologic symptoms, which can include congenital ocular motor apraxia (OMA). OMA is the inability to voluntarily initiate saccades and patients are frequently observed thrusting their heads in the target direction of focus. Additionally observed symptoms include frequent cyclic deviations of the eyes, including periodic alternating gaze deviation, periodic alternating skew deviation, periodic alternating torsional deviation, and a lateral alternating skew deviation that produces an alternating hyperdeviation of the abducting eye. Wheel rolling torsional eye movements from extreme encyclodivergence and extreme incyclodivergence have also been observed in patients with periodic alternating skew deviation and paroxysmalskew deviation [91]. Brodsky et al. also suggested that a cyclical component underlies JS based on similarities between the abnormal breathing patterns and neuro-ophthalmologic features in a patient with JS who demonstrated episodic hyperpnea and apnea by Marie Joubert and intermittent nystagmus on eye movement recordings [91].

Oculomotor Apraxia is often noticed after infancy, which may be due to limited awareness of how it presents in the very young [92]. Most children with OMA present with propulsion of the head as a way to compensate for their inability to initiate saccades [9,12,93]. Horizontal head titubation has also been reported in infants and young children [84]. Oculomotor Apraxia is the phenotype with the largest number of mutated genes associated with it (Figure 4E). Twenty-five genes have been reported, including ODF1, CLAUPI, AHI1/TMEM67, CEP104, INPP5E, AHI1, CEP290, C2CD3, POC1B,
KIAA0556, TMEM67, CC2D2A, CEP120, KIAA07593, TMEM138, MSK1, NPHP1, CSPP1, RPGRIP1, TCTN1, TMEM321, B9D1, KIAA0586, and C5orf42. Among them, AHI1 has been found in the most cases of OMA. Despite the many identified genes, no abnormal gene has been found in numerous cases, and 17% of incidences are attributed to unknown genetic mutations.

7.1.2. Nystagmus and Strabismus

Abnormal eye movements, including primary position nystagmus, are a common feature in JS [11,14,43,57,65,67,72,73,77,84–87,90,94–105]. Fluxes in gaze holding, an early symptom, were described in a study of six patients with JS. Although the conjugate pendular nystagmus demonstrated before the age of 6 months is consistent with infantile nystagmus, the irregularities in conjugate eye movements of the subjects set apart the nystagmus found in JS from other forms of infantile nystagmus. The horizontal pendular nystagmus found in the patients was said to be similar to the periodic nystagmus in lesions of the uvula and nodulus [93]. Translation of the velocity signals transmitted by vestibular, pontine, and inferior olivary nuclei into the eye position is the basis for stable gaze holding [106].

Additionally, the see-saw nystagmus observed in this cohort was proposed to be associated with defects in the interstitial nucleus of Cajal (INC) located in the midbrain [93], since the INC is important in helping translate the vertical and torsional eye velocity signals transmitted by crossed and uncrossed inputs into position signals [106–108]. It was proposed that the loss of certain crossed inputs in JS patients may cause an imbalance of velocity inputs which leads to unstable gaze holding [93]. This is supported by studies of JS patients that point to decussation of the superior cerebellar peduncles and pyramidal tracts [10,109–112].

Nystagmus has been associated with mutations in the following genes: MKS1, TCTN3/TCTN2, ARL13B, TMEM237, CEP120, CCD2D2A, CEP290, INPP5E, AHI1, POClB, RPGRIP1L, KIAA0556, KIAA0586, AHI1/NPHP1, C5orf42, TMEM67, and CSPP1. AHI1 gene mutations are the most frequently correlated with nystagmus (Figure 4F).

Strabismus is frequent in JS, as in other diseases associated with non-progressive cerebral or cerebellar abnormalities [113], and in one small series it was the most common neuro-ophthalmologic abnormality [113]. It can present as horizontal or vertical misalignment, esotropia or exotropia, fixed or alternating, but most often it presents as elevation of the abducting eye and depression of the adducting eye in lateral gaze [8–10,21,76,80,95,114,115]. In a study of neuro-ophthalmological findings in pediatric patients with chronic ataxia, it was found that diseases associated with non-progressive cerebral or cerebellar abnormalities like JS and related disorders were associated with high prevalence of strabismus. Four out of five of the patients with JS surveyed displayed neuro-ophthalmologic features, the most common feature being strabismus [113].

TMEM237 gene mutation was most common in JS patients with strabismus (31% of cases). The protein product of this gene, a four-pass transmembrane protein that localizes to the ciliary transition zone, is known to be involved in ciliogenesis and Wnt signaling [20] (Figure 4G). Other genes identified with this phenotype include AHI1, TMEM67, CEP290, CEOP120, RPGRIP1L, C5orf42, MKS1, and KIAA0586.

7.2. Ptosis

Ptosis can be unilateral or bilateral and of varying severity in JS [65,77,97,99,101,102,114–116]. It occurred in 29% (28/98) of patients with JS assessed in one recent series [35]. It is found almost exclusively in children, but bilateral ptosis developed in one young adult in whom it was thought to be due either to progression of JS or to fibrocystic changes in the midbrain caused by ventriculoperitoneal shunting [117].

Mutation of the centrosome and spindle pole-associated factor-1 gene (CSPP1) is the most common mutation associated with individuals with JS and ptosis (Figure 4H). The CSPP1 protein localizes to the centrosome and is important in ciliogenesis [85]. One study of patients with CSPP1-related JS...
reported ptosis in 15/19 individuals with the biallelic truncating mutations [85]; another study found bilateral ptosis in 4/6 patients with CSP1-related JS [86]. Additional genes implicated in JS-related ptosis include AHI1, CEP290, KIAA586, RPGRIP1L, TMEM67, INPP5E, KIAA0556, and MSK1 (Figure 4), although one recent series did not find ptosis in subjects with mutations of AHI1 or KIAA0586 [35].

8. Conclusions

Joubert Syndrome is a group of complex multi-organ diseases that frequently present with ocular manifestations. The myriad disease presentations can range from mild ocular motility defects that improve with age to severe retinal degeneration that causes blindness at birth. The growing list of identified genetic mutations highlights the importance of the structure and function of primary cilia in the pathogenesis of JS. Development of animal models and targeted gene therapies will help advance personalized treatments for patients with this challenging group of diseases.

Author Contributions: S.F.W., T.J.K., K.N., E.B.K., A.Y.W., V.B.M., and Y.S. contributed to manuscript preparation.

Funding: This work was supported by NIH/NEI K08-EY022058 (Y.S.), R01-EY025295 (Y.S.), VA merit CX001298 (Y.S.), Ziegler Foundation for the Blind (Y.S.), Showalter Foundation (Y.S.), Children’s Health Research Institute Award (Y.S.). Research for Prevention of Blindness Unrestricted grant (Stanford Ophthalmology), American Glaucoma Society (Y.S.), Lowe syndrome association (Y.S.), and Knights Templar Eye Foundation (Y.S.). NIH/NEI P30 Vision Center grant to Stanford Ophthalmology department. Y.S. is a Laurie Kraus Lacob Faculty Scholar in Pediatric Translational Medicine.

Acknowledgments: We thank Hu Yang for thoughtful comments during the preparation of this manuscript.

Conflicts of Interest: The authors declare no competing or financial interests.

References

1. Joubert, M.; Eisenring, J.J.; Robb, J.P.; Andermann, F. Familial agenesis of the cerebellar vermis. A syndrome of episodic hyperpnea, abnormal eye movements, ataxia, and retardation. *Neurology* 1969, 19, 813–825. [CrossRef] [PubMed]
2. Maria, B.L.; Boltshauser, E.; Palmer, S.C.; Tran, T.X. Clinical features and revised diagnostic criteria in Joubert syndrome. *J. Child Neurol.* 1999, 14, 583–590, discussion 590-591. [CrossRef] [PubMed]
3. Boltshauser, E.; Isler, W. Joubert syndrome: episodic hyperpnea, abnormal eye movements, retardation and ataxia, associated with dysplasia of the cerebellar vermis. *Neuropadiatrie* 1977, 8, 57–66. [CrossRef] [PubMed]
4. Parisi, M.; Glass, I. Joubert Syndrome. In *GeneReviews®*; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J., Stephens, K., Amemiya, A., Eds.; University of Washington, Seattle: Seattle, WA, USA, 1993.
5. Brancati, F.; Dallapiccola, B.; Valente, E.M. Joubert Syndrome and related disorders. *Orphanet J. Rare Dis.* 2010, 5, 20. [CrossRef]
6. Romani, M.; Micalizzi, A.; Valente, E.M. Joubert syndrome: Congenital cerebellar ataxia with the molar tooth. *Lancet Neurol.* 2013, 12, 894–905. [CrossRef]
7. Hildebrandt, F.; Benzing, T.; Katsanis, N. Ciliopathies. *N. Engl. J. Med.* 2011, 364, 1533–1543. [CrossRef] [PubMed]
8. Lambert, S.R.; Kriss, A.; Gresty, M.; Benton, S.; Taylor, D. Joubert syndrome. *Arch. Ophthalmol.* 1989, 107, 709–713. [CrossRef] [PubMed]
9. Khan, A.O.; Oystreck, D.T.; Seidahmed, M.Z.; AlDrees, A.; Elmalik, S.A.; Alorainy, I.A.; Salih, M.A. Ophthalmic features of Joubert syndrome. *Ophthalmology* 2008, 115, 2286–2289. [CrossRef] [PubMed]
10. Maria, B.L.; Hoang, K.B.; Tusa, R.J.; Mancuso, A.A.; Hamed, L.M.; Quisling, R.G.; Hove, M.T.; Fennell, E.B.; Booth-Jones, M.; Ringdahl, D.M.; et al. “Joubert syndrome” revisited: key ocular motor signs with magnetic resonance imaging correlation. *J. Child Neurol.* 1997, 12, 423–430. [CrossRef] [PubMed]
11. Sturm, V.; Leiba, H.; Menke, M.N.; Valente, E.M.; Poretti, A.; Landau, K.; Boltshauser, E. Ophthalmological findings in Joubert syndrome. *Eye (Lond)* 2010, 24, 222–225. [CrossRef] [PubMed]
12. Hodgkins, P.R.; Harris, C.M.; Shawkat, F.S.; Thompson, D.A.; Chong, K.; Timms, C.; Russell-Eggitt, I.; Taylor, D.S.; Kriss, A. Joubert syndrome: Long-term follow-up. *Dev. Med. Child Neurol.* 2004, 46, 694–699. [CrossRef] [PubMed]
13. Gill, H.; Muthusamy, B.; Atan, D.; Williams, C.; Ellis, M. Joubert syndrome presenting with motor delay and oculomotor apraxia. *Case Rep. Pediatr.* **2011**, **2011**, 262641. [CrossRef] [PubMed]

14. Kroes, H.Y.; Monroe, G.R.; van der Zwaag, B.; Duran, K.J.; de Kovel, C.G.; van Roosmalen, M.J.; Harakalova, M.; Nijman, I.J.; Kloosterman, W.P.; Giles, R.H.; et al. Joubert syndrome: Genotyping a Northern European patient cohort. *Eur. J. Hum. Genet.* **2016**, **24**, 214–220. [CrossRef] [PubMed]

15. Parisi, M.A.; Doherty, D.; Chance, P.F.; Glass, I.A. Joubert syndrome (and related disorders) (OMIM 213300). *Eur. J. Hum. Genet.* **2007**, **15**, 511–521. [CrossRef] [PubMed]

16. Sniou, M.; Schwartzzentruber, J.; Hamdan, F.F.; Osphina, L.H.; Patry, L.; Labuda, D.; Massicotte, C.; Dobrzniecka, S.; Capo-Chichi, J.-M.; Papillon-Cavanagh, S.; et al. Mutations in C5ORF42 cause Joubert syndrome in the French Canadian population. *Am. J. Hum. Genet.* **2012**, **90**, 693–700. [CrossRef] [PubMed]

17. Sniou, M.; Hamdan, F.F.; Mc Knight, D.; Davis, E.; Mandel, H.; Schwartzzentruber, J.; Martin, B.; Patry, L.; Nassif, C.; Dione-Laporte, A.; et al. Joubert Syndrome in French Canadians and Identification of Mutations in CEP104. *Am. J. Hum. Genet.* **2015**, **97**, 744–753. [CrossRef] [PubMed]

18. Sniou, M.; Hamdan, F.F.; Schwartzzentruber, J.A.; Patry, L.; Osphina, L.H.; Shevell, M.I.; Desilets, V.; Dobrzniecka, S.; Mathonnet, G.; Lemyre, E.; et al. Mutations in TMEM231 cause Joubert syndrome in French Canadians. *J. Med. Genet.* **2012**, **49**, 636–641. [CrossRef] [PubMed]

19. Edvardson, S.; Shaag, A.; Zenvirt, S.; Erlich, Y.; Hannon, G.J.; Danske, A.L.; Gomori, J.M.; Etstein, J.; Elpeleg, O. Joubert syndrome 2 (JBT2) in Ashkenazi Jews is associated with a TMEM216 mutation. *Am. J. Hum. Genet.* **2010**, **86**, 93–97. [CrossRef] [PubMed]

20. Huang, L.; Szynzanska, K.; Jensen, V.L.; Janecke, A.R.; Erlich, Y.; Hannon, G.J.; Shanske, A.L.; Gomori, J.M.; Ekstein, J.; et al. Molecular genetic analysis of 30 families with Joubert syndrome. *Clin. Genet.* **2016**, **89**, 713–730. [CrossRef] [PubMed]

21. Shaheen, R.; Shamseldin, H.E.; Loucks, C.M.; Seidahmed, M.Z.; Ansari, S.; Ibrahim Khalil, M.; Al-Yacoub, N.; Davis, E.E.; Mola, N.A.; Szymanska, K.; et al. Mutations in CESP1, encoding a core centrosomal protein, cause a range of ciliopathy phenotypes in humans. *Am. J. Hum. Genet.* **2014**, **94**, 73–79. [CrossRef] [PubMed]

22. Suzuki, T.; Miyake, N.; Tsurusaki, Y.; Okamoto, N.; Alkindy, A.; Inaba, A.; Sato, M.; Ito, S.; Muramatsu, K.; Kimura, S.; et al. Molecular genetic analysis of 30 families with Joubert syndrome. *Clin. Genet.* **2010**, **89**, 96–112. [CrossRef] [PubMed]

23. Doherty, D.; Parisi, M.A.; Finn, L.S.; Gunay-Aygun, M.; Al-Mateen, M.; Bates, D.; Clericuzio, C.; Demir, H.; Dorschner, M.; van Essen, A.J.; et al. Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis). *J. Med. Genet.* **2010**, **47**, 8–21. [CrossRef] [PubMed]

24. Iannicelli, M.; Brancati, F.; Mouougou-Zerelli, S.; Mazzotta, A.; Thomas, S.; Elkhartoufi, N.; Travaglini, L.; Gomes, C.; Ardissino, G.L.; Bertini, E.; et al. Novel TMEM67 mutations and genotype-phenotype correlates in meckelina-related ciliopathies. *Hum. Mutat.* **2010**, **31**, E1319–E1331. [CrossRef] [PubMed]

25. Valente, E.M.; Marsh, S.E.; Castori, M.; Dixon-Salazar, T.; Bertini, E.; Al-Gazali, L.; Messer, J.; Barbot, C.; Woods, C.G.; Bolthasauer, E.; et al. Distinguishing the four genetic causes of Joubert syndrome related disorders. *Am. J. Med. Genet. A* **2011**, **152A**, 511–521. [CrossRef] [PubMed]

26. Senocak, E.U.; Oğuz, K.K.; Haliloglu, G.; Toçoju, M.; Cila, A. Structural abnormalities of the brain other than molar tooth sign in Joubert syndrome-related disorders. *Diagn Interv. Radiol.* **2010**, **16**, 3–6. [CrossRef] [PubMed]

27. Bachmann-Gagescu, R.; Dempsey, J.C.; Phelps, I.G.; O’Rooke, B.J.; Knutzen, D.M.; Rue, T.C.; Ishak, G.E.; Isabella, C.R.; Gorden, N.; Adkins, J.; et al. Joubert syndrome: A model for untangling recessive disorders with extreme genetic heterogeneity. *J. Med. Genet.* **2015**, **52**, 514–522. [CrossRef] [PubMed]

28. Lehman, A.M.; Eydoux, P.; Doherty, D.; Glass, I.A.; Chitayat, D.; Chung, B.Y.H.; Langlois, S.; Yong, S.L.; Lowry, R.B.; Hildebrandt, F.; et al. Co-occurrence of Joubert syndrome and Jeune asphyxiating thoracic dystrophy. *Am. J. Hum. Genet. A* **2010**, **152A**, 1411–1419. [CrossRef]

29. Shaheen, R.; Schmidts, M.; Faqeih, E.; Hashem, A.; Lausch, E.; Holder, I.; Superti-Furga, A.; UK10K Consortium; Mitchison, H.M.; Almoheer, A.; et al. A founder CEP120 mutation in Jeune asphyxiating thoracic dystrophy expands the role of centriolar proteins in skeletal ciliopathies. *Hum. Mol. Genet.* **2015**, **24**, 1410–1419. [CrossRef]
30. Adams, N.A.; Awadein, A.; Toma, H.S. The retinal ciliopathies. *Ophthalmic Genet.* 2007, 28, 113–125. [CrossRef]

31. Vilboux, T.; Doherty, D.A.; Glass, I.A.; Parisi, M.A.; Phelps, I.G.; Cullinane, A.R.; Zein, W.; Brooks, B.P.; Heller, T.; Soldatos, A.; et al. Molecular genetic findings and clinical correlations in 100 patients with Joubert syndrome and related disorders prospectively evaluated at a single center. *Genet. Med.* 2017, 19, 875–882. [CrossRef]

32. Parisi, M.A.; Doherty, D.; Eckert, M.L.; Shaw, D.W.W.; Ozyurek, H.; Aysun, S.; Giray, O.; Al Swaid, A.; Al Shahwan, S.; Dohayn, N.; et al. AHI1 mutations cause both retinal dystrophy and renal cystic disease in Joubert syndrome. *J. Med. Genet.* 2006, 43, 334–339. [CrossRef][PubMed]

33. Westfall, J.E.; Hoyt, C.; Liu, Q.; Hsiao, Y.-C.; Pierce, E.A.; Page-McCaw, P.S.; Ferland, R.J. Retinal degeneration and failure of photoreceptor outer segment formation in mice with targeted deletion of the Joubert syndrome gene, Ahi1. *J. Neurosci.* 2010, 30, 8759–8768. [CrossRef][PubMed]

34. Saraiva, J.M.; Baraitser, M. Joubert syndrome: a review. *Am. J. Med. Genet.* 1992, 43, 726–731. [CrossRef][PubMed]

35. Brooks, B.P.; Zein, W.M.; Thompson, A.H.; Mokhtarzadeh, M.; Doherty, D.A.; Parisi, M.; Glass, I.A.; Malicdan, M.C.; Vilboux, T.; Vemulapalli, M.; et al. Joubert Syndrome: Ophthalmological Findings in Correlation with Genotype and Hepatorenal Disease in 99 Patients Prospectively Evaluated at a Single Center. *Ophthalmology* 2018. [CrossRef][PubMed]

36. Baba, S.; Takeshita, E.; Yamazaki, H.; Tarashima, M.; Sasaki, M. Disruption of the Photoreceptor Inner Segment-Outer Segment Junction in a 6-Year-Old Girl with Joubert Syndrome. *Neuroophthalmology* 2017, 41, 19–23. [CrossRef]

37. Dixon-Salazar, T.; Silhavy, J.L.; Marsh, S.E.; Louie, C.M.; Scott, L.C.; Gururaj, A.; Al-Gazali, L.; Al-Tawari, A.A.; Kaysersli, H.; Sztiria, L.; et al. Mutations in the AHI1 gene, encoding jouberin, cause Joubert syndrome with cortical polymicrogyria. *Am. J. Hum. Genet.* 2004, 75, 979–987. [CrossRef]

38. Eley, L.; Gabrieldes, C.; Adams, M.; Johnson, C.A.; Hildebrandt, F.; Sayer, J.A. Jouberin localizes to collecting ducts and interacts with nephrocystin-1. *Kidney Int.* 2008, 74, 1139–1149. [CrossRef]

39. Romani, S.; Illi, B.; De Mori, R.; Savino, M.; Gleeson, J.G.; Valente, E.M. The ciliary proteins Meckelin and Jouberin are required for retinoic acid-dependent neural differentiation of mouse embryonic stem cells. *Differentiation* 2014, 87, 134–146. [CrossRef]

40. Louie, C.M.; Caridi, G.; Lopes, V.S.; Brancati, F.; Kispert, A.; Lancaster, M.A.; Schlossman, A.M.; Otto, E.A.; Leitges, M.; Gröne, H.-J.; et al. AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis. *Nat. Genet.* 2010, 42, 175–180. [CrossRef]

41. Jacoby, M.; Cox, J.J.; Gayral, S.; Hampshire, D.J.; Ayub, M.; Blockmans, M.; Pernet, E.; Kisseleva, M.V.; Compère, P.; Schiffrmann, S.N.; et al. INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse. *Nat. Genet.* 2009, 41, 1027–1031. [CrossRef]

42. Chawla, R.; Bypareddy, R.; Vekaria, L.; Venkatesh, P.; Ananthashayana, V.H. Fundus findings in a case of Joubert syndrome. *Indian J. Ophthalmol.* 2017, 65, 329–330. [CrossRef]

43. Abouammoh, M.A.; Al-Shbani, S.K.; Alhawwas, A.; Bosley, T.M. Coats-like retinopathy in Joubert syndrome. *J. AAPOS* 2016, 20, 372–374. [CrossRef][PubMed]

44. Yzer, S.; den Hollander, A.I.; Lopez, I.; Pott, J.-W.R.; de Bie, E.P.H.; Cremers, F.P.M.; Koenekoop, R.K.; van den Born, L.I. Ocular and extra-ocular features of patients with Leber congenital amaurosis and mutations in CEP290. *Mol. Vis.* 2012, 18, 412–425.

45. Valente, E.M.; Silhavy, J.L.; Brancati, F.; Barrano, G.; Krishnaswami, S.R.; Castori, M.; Lancaster, M.A.; Bolthäuser, E.; Boccone, L.; Al-Gazali, L.; et al. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nat. Genet.* 2006, 38, 623–625. [CrossRef][PubMed]

46. Yilmaz, S.; Biler, E.D.; Solmaz, A.E.; Serdaroglu, G.; Tekin, H.G.; Gokben, S. Optic disc drusen mimicking papilledema in an infant with Joubert syndrome. *Genet. Couns.* 2015, 26, 35–39.

47. Erkkilä, H. Clinical appearance of optic disc drusen in childhood. *Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.* 1975, 193, 1–18.

48. Wilkins, J.M.; Pomeranz, H.D. Visual manifestations of visible and buried optic disc drusen. *J. Neuroophthalmol.* 2004, 24, 125–129. [CrossRef]

49. Chung, D.C.; Traboulsi, E.I. Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions. *J. AAPOS* 2009, 13, 587–592. [CrossRef]
Gene evidence for Joubert syndrome and other cerebello-oculo-renal (CORK) syndromes is accumulating rapidly, and the molecular basis of these conditions is being elucidated. Here we review recent advances in the understanding of these disorders, with a focus on the role of the primary cilium, and discuss the relevance of these studies to other disease states involving the primary cilium. The primary cilium is a microtubule-based projection, typically found at the apical surface of epithelial cells and on neuronal processes. It acts as a sensor for extracellular cues, and mutants in primary ciliopathy genes can result in a variety of disease phenotypes, including those observed in Joubert syndrome and related disorders.

Genes 2018, 9, 605

50. Waters, A.M.; Beales, P.L. Ciliopathies: an expanding disease spectrum. Pediatr. Nephrol. 2011, 26, 1039–1056. [CrossRef]

51. Heher, K.L.; Traboulsi, E.I.; Maumenee, I.H. The natural history of Leber’s congenital amaurosis. Age-related findings in 35 patients. Ophthalmology 1992, 99, 241–245. [CrossRef]

52. Koeneke, R.K. An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv. Ophthalmol. 2004, 49, 379–398. [CrossRef] [PubMed]

53. Sohocki, M.M.; Sullivan, L.S.; Mintz-Hittner, H.A.; Birch, D.; Heckenlively, J.R.; Freund, C.L.; McNnes, R.R.; Daiger, S.P. A range of clinical phenotypes associated with mutations in CRX, a photoreceptor transcription-factor gene. Am. J. Hum. Genet. 1998, 63, 1307–1315. [CrossRef] [PubMed]

54. Tzekov, R.T.; Liu, Y.; Sohocki, M.M.; Zack, D.J.; Daiger, S.P.; Heckenlively, J.R.; Birch, D.G. Autosomal dominant retinal degeneration and bone loss in patients with a 12-bp deletion in the CRX gene. Investig. Ophthalmol. Vis. Sci. 2001, 42, 1319–1327.

55. Nichols, L.L.; Alur, R.P.; Boobalan, E.; Sergeev, Y.V.; Caruso, R.C.; Stone, E.M.; Swaroop, A.; Johnson, M.A.; Brooks, B.P. Two novel CRX mutant proteins causing autosomal dominant Leber congenital amaurosis interact differently with NRL. Hum. Mutat. 2010, 31, E1472–E1483. [CrossRef] [PubMed]

56. Zou, X.; Yao, F.; Liang, X.; Xu, F.; Li, H.; Sui, R.; Dong, F. De novo mutations in the cone-rod homebox gene associated with leber congenital amaurosis in Chinese patients. Ophthalmic Genet. 2015, 36, 21–26. [CrossRef]

57. Beck, B.B.; Phillips, J.B.; Bartram, M.P.; Wegner, J.; Thoenes, M.; Pannes, A.; Sampson, J.; Heller, R.; Göbel, H.; Koerber, F.; et al. Mutation of POClIB in a severe syndromic retinal ciliopathy. Hum. Mutat. 2014, 35, 1153–1162. [CrossRef] [PubMed]

58. Chacon-Camacho, O.F.; Zenteno, J.C. Review and update on the molecular basis of Leber congenital amaurosis. World J. Clin. Cases 2015, 3, 112–124. [CrossRef]

59. Gregory-Evans, C.Y.; Williams, M.J.; Halford, S.; Gregory-Evans, K. Ocular coloboma: A reassessment in the age of molecular neuroscience. J. Med. Genet. 2004, 41, 881–891. [CrossRef]

60. Arrigoni, F.; Romaniello, R.; Peruzzo, D.; De Luca, A.; Parazzini, C.; Valente, E.M.; Borgatti, R.; Trulzii, F. Anterior mesencephalic cap dysplasia: Novel brain stem malformative features associated with Joubert Syndrome. AJNR Am. J. Neuroradiol. 2012, 33, 229–233. [CrossRef] [PubMed]

61. Zhang, K.; Meng, C.; Ma, J.; Gao, M.; Lv, Y.; Liu, Y.; Gai, Z. Novel ODF1 frameshift mutation in a Chinese boy with Joubert syndrome: A case report and literature review. Clin. Dysmorphol. 2017, 26, 135–141. [CrossRef]

62. Enokizono, M.; Aida, N.; Niwa, T.; Osaka, H.; Naruto, T.; Kurosawa, K.; Ohba, C.; Suzuki, T.; Saito, H.; Goto, T.; et al. Neuroimaging findings in Joubert syndrome with C5orf42 gene mutations: A milder form of molar tooth sign and vermian hypoplasia. J. Neurol. Sci. 2017, 367, 7–12. [CrossRef] [PubMed]

63. Malikdan, M.C.V.; Vilboux, T.; Stephen, J.; Maglic, D.; Mian, L.; Konzman, D.; Guo, J.; Yildirimli, D.; Bryant, J.; Fischer, R.; et al. Mutations in human homologue of chicken talpid3 gene (KIAA0586) cause a hybrid ciliopathy with overlapping features of Jeune and Joubert syndromes. J. Med. Genet. 2015, 52, 830–839. [CrossRef]

64. Bachmann-Gagescu, R.; Phelps, I.G.; Dempsey, J.C.; Sharma, V.A.; Ishak, G.E.; Boyle, E.A.; Wilson, M.; Marques Lourenço, C.; Arslan, M.; University of Washington Center for Mendelian Genomics; et al. KIAA0586 is Mutated in 2015, 36, 831–835. [CrossRef] [PubMed]

65. Makino, S.; Tampo, H. Ocular findings in two siblings with Joubert syndrome. Clin. Ophthalmol. 2014, 8, 229–233. [CrossRef] [PubMed]

66. Thomas, S.; Wright, K.J.; Le Corre, S.; Micalizzi, A.; Romani, M.; Abhyankar, A.; Saada, J.; Perrault, L.; Amiel, J.; Litzler, J.; et al. A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium. Hum. Mutat. 2014, 35, 137–146. [CrossRef] [PubMed]

67. İncecek, F.; Hergüner, M.O.; Altunbaşak, Ş.; Gleeson, J.G. Joubert syndrome: Report of 11 cases. Turk. J. Pediatr. 2012, 54, 605–611. [PubMed]

68. Satran, D.; Pierpont, M.E.; Dobyns, W.B. Cerebello-oculo-renal syndromes including Arima, Senior-Löken and COACH syndromes: More than just variants of Joubert syndrome. Am. J. Med. Genet. 1999, 86, 459–469. [CrossRef]

69. Brancati, F.; Iannicelli, M.; Travaglini, L.; Mazzotta, A.; Bertini, E.; Boltshauser, E.; D’Arrigo, S.; Emma, F.; Fazzi, E.; Gallizzi, R.; et al. MKS3/TMEM67 mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement. Hum. Mutat. 2009, 30, E432–E442. [CrossRef] [PubMed]
70. Doherty, D. Joubert syndrome: Insights into brain development, cilium biology, and complex disease. *Semin. Pediatr. Neurosurg.* 2009, 16, 143–154. [CrossRef]
71. Apostolou, T.; Nikolopoulou, N.; Theodoridis, M.; Koumoustitis, V.; Pavlopoulou, E.; Chondros, D.; Billis, A. Late onset of renal disease in nephronophthisis with features of Joubert syndrome type B. *Nephrol. Dial. Transplant.* 2001, 16, 2412–2415. [CrossRef]
72. Couch, S.M.; Brodie, S.E.; Leavitt, J.A.; Brodsky, M.C. Something to sink your teeth into. *Surv. Ophthalmol.* 2011, 56, 544–549. [CrossRef] [PubMed]
73. Papanagnu, E.; Klaehn, L.D.; Bang, G.M.; Ghabban, R.; Mohnney, B.G.; Brodsky, M.C. Congenital ocular motor apraxia with wheel-rolling ocular torsion-a neurodevelopmental phenotype of Joubert syndrome. *J. AAPOS* 2014, 18, 404–407. [CrossRef] [PubMed]
74. Johnston, J.J.; Lee, C.; Wentzensen, I.M.; Parisi, M.A.; Crenshaw, M.M.; Sapp, J.C.; Gross, J.M.; Wallingford, J.B.; Biesecker, L.G. Nosological delineation of congenital ocular motor apraxia type Cogan: An observational study. *Orphanet. J. Rare Dis.* 2016, 11, 104. [CrossRef] [PubMed]
75. Stephen, J.; Vilboux, T.; Mian, L.; Kuptanon, C.; Sinclair, C.M.; Yildirimli, D.; Maynard, D.M.; Bryant, J.; Fischer, R.; Vemulapalli, M.; et al. Mutations in KIAA0753 cause Joubert syndrome associated with growth hormone deficiency. *Hum. Genet.* 2017, 136, 399–408. [CrossRef] [PubMed]
76. Wente, S.; Schröder, S.; Buckard, J.; Büttel, H.-M.; von Deimling, F.; Häussler, M.; Hübschle, S.; Kinder, S.; Kurlenmann, G.; et al. Mutation analysis and CEP120 in a child with a novel Joubert and oral-facial-digital overlap syndrome. *Cold Spring Harb. Mol. Case Stud.* 2017, 3. [CrossRef] [PubMed]
77. Roosing, S.; Rosti, R.O.; Rosti, B.; de Vrieze, E.; Silhavy, J.L.; van Wijk, E.; Wakeling, E.; Gleeson, J.G. Identification of a homozygous nonsense mutation in KIAA0556 in a consanguineous family displaying Joubert syndrome. *Hum. Genet.* 2016, 135, 919–921. [CrossRef]
78. Slaats, G.G.; Isabella, C.R.; Kroes, H.Y.; Dempsey, J.C.; Gremmels, H.; Monroe, G.R.; Phelps, I.G.; Duran, K.J.; Adkins, J.; Kumar, S.A.; et al. MKS1 regulates ciliary INPP5E levels in Joubert syndrome. *J. Med. Genet.* 2016, 53, 62–72. [CrossRef]
79. Roosing, S.; Romani, M.; Isrie, M.; Rosti, R.O.; Micalizzi, A.; Musaev, D.; Mazza, T.; Al-Gazali, L.; Altunoglu, U.; Bolthausen, E.; et al. Mutations in CEP120 cause Joubert syndrome as well as complex ciliopathy phenotypes. *J. Med. Genet.* 2016, 53, 608–615. [CrossRef]
80. Gagliardi, C.; Brenna, V.; Romaniello, R.; Arrigoni, F.; Tavano, A.; Romani, M.; Valente, E.M.; Borgatti, R. Cognitive rehabilitation in a child with Joubert Syndrome: Developmental trends and adaptive changes in a single case report. *Res. Dev. Disabil.* 2015, 47, 375–384. [CrossRef]
81. Hsu, C.C.-T.; Kwan, G.N.C.; Bhuta, S. High-Resolution Diffusion Tensor Imaging and Tractography in Joubert Syndrome: Beyond Molar Tooth Sign. *Pediatr. Neurol.* 2015, 53, 47–52. [CrossRef]
82. Thomas, S.; Cantagrel, V.; Mariani, L.; Serre, V.; Lee, J.-E.; Elkhartoufi, N.; de Lonlay, P.; Desguerre, I.; Gagliardi, C.; Brenna, V.; Romaniello, R.; Arrigoni, F.; Tavano, A.; Romani, M.; Valente, E.M.; Moorjani, S.; Zielenski, J. Identification of a novel ARL13B variant in a Joubert syndrome-affected patient with retinal impairment and obesity. *Eur. J. Hum. Genet.* 2015, 23, 621–627. [CrossRef] [PubMed]
83. Dekair, L.H.; Kamel, H.; El-Bashir, H.O. Joubert syndrome labeled as hypotonic cerebral palsy. *Neurosciences (Riyadh)* 2014, 19, 233–235. [PubMed]
84. Poretti, A.; Christen, H.-J.; Elton, L.E.; Baumgartner, M.; Korenke, G.C.; Sukhudy, B.; Hedhey, S.; Cross, E.; Steinlin, M.; Bolthausen, E. Horizontal head titubation in infants with Joubert syndrome: a new finding. *Dev. Med. Child Neurol.* 2014, 56, 1016–1020. [CrossRef] [PubMed]
85. Tuz, K.; Bachmann-Gagescu, R.; O’Day, D.R.; Hua, K.; Isabella, C.R.; Phelps, I.G.; Stolarski, A.E.; O’Roak, B.J.; Dempsey, J.C.; Lourenco, C.; et al. Mutations in CSPP1 cause primary cilia abnormalities and Joubert syndrome with or without Jeune asphyxiating thoracic dystrophy. *Am. J. Hum. Genet.* 2014, 94, 62–72. [CrossRef] [PubMed]
86. Akizu, N.; Silhavy, J.L.; Rosti, R.O.; Scott, E.; Fenstermaker, A.G.; Schroth, J.; Zaki, M.S.; Sanchez, H.; Gupta, N.; Kabra, M.; et al. Mutations in CSPP1 lead to classical Joubert syndrome. *Am. J. Hum. Genet.* 2014, 94, 80–86. [CrossRef] [PubMed]
87. Nag, C.; Ghosh, M.; Das, K.; Ghosh, T. Joubert syndrome: The molar tooth sign of the mid-brain. *Ann. Med. Health Sci. Res.* 2013, 3, 291–294. [CrossRef] [PubMed]
88. Théoret, H.; Gleeson, J.; Pascual-Leone, A. Neurophysiologic characterization of motor and sensory projections in Joubert syndrome. *Clin. Neurophysiol.* 2013, 124, 2283–2284. [CrossRef]
99. Sanders, A.A.W.M.; de Vrieze, E.; Alazami, A.M.; Alzahrani, F.; Malarkey, E.B.; Sorusch, N.; Tebbe, L.; et al. Using next-generation sequencing as a genetic diagnostic tool in rare autosomal recessive neurologic Mendelian disorders. *Neurobiol. Aging* **2013**, *34*, 2442.e11–2442.e17. [CrossRef]

100. Chafai-Elalaoui, S.; Chalon, M.; Elkhartoufi, N.; Kriouele, Y.; Mansouri, M.; Atti, P.; Poretti, A.; Boltshauser, E.; Loenneker, T.; Valente, E.M.; Brancati, F.; Il'yasov, K.; Huisman, T.a.G.M. Diffusion tensor imaging in Joubert syndrome. *AJNR Am. J. Neuroradiol.* **2007**, *28*, 1929–1933. [CrossRef] [PubMed]

101. Sönmez, F.; Güzünler-Şen, M.; Yılmaz, D.; Cömertpay, G.; Heise, M.; Çırak, S.; Uyanık, G. Development of disorders. *Ann. Neurol.* **2006**, *59*, 527–534. [CrossRef] [PubMed]

102. Purkait, R.; Basu, R.; Das, R.; Chatterjee, U. Association of Joubert syndrome and Hirschsprung disease. *Indian J. Pediatr.* **2016**, *83*, 1505. [CrossRef]

103. Valente, E.M.; Brancati, F.; Silhavy, J.L.; Castori, M.; Marshall, S.E.; Barrano, G.; Bertini, E.; Boltshauser, E.; Zaki, M.S.; Abdel-Aleem, A.; et al. KIAA0556 is a novel ciliary basal body component mutated in Joubert syndrome: A case report. *Codas* **2016**, *28*, 823–827. [CrossRef] [PubMed]

104. Huppke, P.; Wegener, E.; Bührer-Rabel, H.; Bolz, H.J.; Zoll, B.; Gärtnert, J.; Bergmann, C. Tectonic gene mutations cause Joubert syndrome-related disorders. *Ann. Neurol.* **2006**, *59*, 527–534. [CrossRef] [PubMed]

105. Helmchen, C.; Rambold, H.; Fuhrly, L.; Büttner, U. Deficits in vertical and torsional eye movements after unilateral and bilateral muscimol inactivation of the interstitial nucleus of Cajal of the alert monkey. *Exp. Brain Res.* **1998**, *119*, 436–452. [CrossRef] [PubMed]

106. Fukushima, K.; Kaneko, C.R.; Fuchs, A.F. The neuronal substrate of integration in the oculomotor system. *Science* **1991**, *252*, 1551–1553. [CrossRef] [PubMed]

107. Helmchen, C.; Rambold, H.; Fuhrly, L.; Büttner, U. Deficits in vertical and torsional eye movements after unilateral and bilateral muscimol inactivation of the interstitial nucleus of Cajal. *Science* **1991**, *252*, 1551–1553. [CrossRef] [PubMed]

108. Crawford, J.D.; Cadera, W.; Vilis, T. Generation of torsional and vertical eye position signals by the interstitial nucleus of Cajal. *Science* **1991**, *252*, 1551–1553. [CrossRef] [PubMed]

109. Yachnis, A.T.; Rorke, L.B. Neuropathology of Joubert syndrome. *J. Child Neurol.* **1999**, *14*, 655–659, discussion 669–672. [CrossRef] [PubMed]

110. Parisi, M.A.; Pinter, J.D.; Glass, I.A.; Field, K.; Maria, B.L.; Chance, P.F.; Mahurin, R.K.; Cramer, S.C. Cerebral and cerebellar motor activation abnormalities in a subject with Joubert syndrome: Functional magnetic resonance imaging (fMRI) study. *J. Child Neurol.* **2004**, *19*, 214–218. [PubMed]

111. Poretti, A.; Boltshauser, E.; Loenneker, T.; Valente, E.M.; Brancati, F.; Il’yasov, K.; Huisman, T.a.G.M. Diffusion tensor imaging in Joubert syndrome. *AJNR Am. J. Neuroradiol.* **2007**, *28*, 1929–1933. [CrossRef] [PubMed]
112. Widjaja, E.; Blaser, S.; Raybaud, C. Diffusion tensor imaging of midline posterior fossa malformations. *Pediatr. Radiol.* 2006, 36, 510–517. [CrossRef] [PubMed]

113. Salman, M.S.; Chodirker, B.N. Neuro-Ophthalmological Findings in Children and Adolescents with Chronic Ataxia. *Neuroophthalmology* 2015, 39, 125–131. [CrossRef] [PubMed]

114. Usta, M.; Urganci, N.; Özçelik, G.; Çetinçelik, Ü.; Kafadar, I.; Özgüven, B.Y. Joubert syndrome and related disorders: A rare cause of intrahepatic portal hypertension in childhood. *Eur. Rev. Med. Pharmacol. Sci.* 2015, 19, 2297–2300. [PubMed]

115. Lee, N.; Nam, S.-O.; Kim, Y.M.; Lee, Y.-J. A neonate with Joubert syndrome presenting with symptoms of Horner syndrome. *Korean J. Pediatr.* 2016, 59, S32–S36. [CrossRef] [PubMed]

116. Stephen, L.A.; Tawamie, H.; Davis, G.M.; Tebbe, L.; Nürnberg, P.; Nürnberg, G.; Thiele, H.; Thoenes, M.; Boltshauser, E.; Uebe, S.; et al. TALPID3 controls centrosome and cell polarity and the human ortholog KIAA0586 is mutated in Joubert syndrome (JBTS23). *eLife* 2015, 4. [CrossRef] [PubMed]

117. Burt, B.; Levine, J.; Le, K. Adult-onset bulbar ptosis in Joubert syndrome. *Clin. Ophthalmol.* 2012, 6, 151–153. [CrossRef]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).